GOA Therapeutics exits stealth with $15.5m alcohol antidote

GOA Therapeutics has emerged from more than a decade of stealth development to unveil GOA26, a preclinical drug candidate designed to rapidly lower blood alcohol concentration (BAC) in patients with acute alcohol intoxication and poisoning. The Dallas-based company announced $15.5 million in total funding raised to date and presented IND-enabling data at the 85th Annual Meeting of the American Association for the Surgery of Trauma in Dallas on 17 September 2026.

In a porcine model, animals given an oral ethanol dose of 1.2 g/kg and then treated with GOA26 showed a 61.3% lower BAC than untreated controls at 20 minutes post-administration. The company said the programme has also progressed through toxicology, safety testing, and manufacturing development, and it plans to file an Investigational New Drug application with the FDA before the end of 2026, with human clinical trials targeted for 2027 subject to regulatory clearance.

A dual-action mechanism

GOA26 pairs an engineered enzyme designed to accelerate ethanol metabolism with a chemical scavenger intended to sequester acetaldehyde, the toxic byproduct produced as the body breaks down alcohol. The rationale is that addressing both ethanol and acetaldehyde simultaneously reduces the risk of life-threatening complications, including respiratory suppression, seizures, and cardiac arrest.

Co-founder and chief scientist Tami Ehrmann Barr said: "Our approach combines an engineered enzyme to accelerate ethanol metabolism with a chemical scavenger to sequester acetaldehyde. The findings presented at AAST provide preclinical proof of concept and mark an important milestone as we work toward human studies."

The company is positioning the initial treatment as an intravenous product for hospital emergency departments and trauma centres.

Market context and competitive landscape

GOA Therapeutics is entering a space that has attracted limited pharmaceutical investment relative to its clinical burden. The company notes there is currently no FDA-approved drug that rapidly lowers BAC in acutely intoxicated patients, a gap that leaves emergency physicians managing complications whilst waiting for the body to clear alcohol naturally, a process that can take many hours.

More than five million patients present to US emergency departments annually with acute alcohol poisoning, according to figures cited in the release, with the global figure exceeding 30 million. The scale of that burden means a safe, effective acute intervention could command significant market interest, but the regulatory path for a novel enzymatic approach in a complex, acutely ill population will require careful clinical design. The FDA will scrutinise safety signals around acetaldehyde sequestration and the speed of ethanol clearance in human subjects, where porcine model data may not translate directly.

Several academic groups have explored alcohol-metabolising enzyme therapies over the years, including catalase- and alcohol oxidase-based approaches, without reaching late-stage clinical development. GOA26's dual-action formulation and the breadth of preclinical work the company describes, spanning protein engineering, formulation, manufacturing, and multiple model systems, may differentiate it from earlier attempts, though the human data that will follow an IND clearance will be the critical test. The company's funding base of $15.5 million is relatively modest for a programme targeting the emergency-medicine channel, and a Series A or strategic partnership announcement is likely to follow as it moves toward first-in-human studies.